This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Leon Speroff, MD
Oregon Health Sciences University Portland

JAMA. 1997;277(19):1515-1516.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—In response to the letter by Drs Hanson and Melzer, clinical trials are designed and performed with Food and Drug Administration (FDA) guidance and according to FDA requirements. To document the protective effect of an estrogen-progesting combination against endometrial hyperplasia, the FDA has required both a placebo group and an unopposed estrogen group in clinical trials such as ours and others (eg, the 3-year National Institutes of Health [NIH]-supported PEPI trial¹).

The statement in the introduction of our article regarding withdrawal bleeding referred to results from our pilot study that did include a cyclical CEE-MPA group. In the "Comment" section, we clearly state that a comparative study with continuous NA-EE₂ and CEE-MPA has not been done and would be helpful to define differences. . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?